Neurogene (NGNE) Competitors $21.72 -0.06 (-0.28%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$33.15 +11.43 (+52.60%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. CDTX, CVAC, AUPH, PRAX, CALT, PAHC, SRPT, DYN, SANA, and RCUSShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Cidara Therapeutics (CDTX), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), Praxis Precision Medicines (PRAX), Calliditas Therapeutics AB (publ) (CALT), Phibro Animal Health (PAHC), Sarepta Therapeutics (SRPT), Dyne Therapeutics (DYN), Sana Biotechnology (SANA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors Cidara Therapeutics CureVac Aurinia Pharmaceuticals Praxis Precision Medicines Calliditas Therapeutics AB (publ) Phibro Animal Health Sarepta Therapeutics Dyne Therapeutics Sana Biotechnology Arcus Biosciences Neurogene (NASDAQ:NGNE) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Do analysts prefer NGNE or CDTX? Neurogene presently has a consensus price target of $46.17, indicating a potential upside of 112.55%. Cidara Therapeutics has a consensus price target of $57.29, indicating a potential downside of 8.28%. Given Neurogene's higher possible upside, equities research analysts clearly believe Neurogene is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media favor NGNE or CDTX? In the previous week, Neurogene had 2 more articles in the media than Cidara Therapeutics. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for Cidara Therapeutics. Neurogene's average media sentiment score of 0.34 beat Cidara Therapeutics' score of 0.00 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cidara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, NGNE or CDTX? Neurogene has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Do insiders & institutionals believe in NGNE or CDTX? 52.4% of Neurogene shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 11.6% of Neurogene shares are owned by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is NGNE or CDTX more profitable? Neurogene's return on equity of -36.16% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -36.16% -32.51% Cidara Therapeutics N/A -73.04%-54.28% Which has stronger earnings & valuation, NGNE or CDTX? Neurogene has higher earnings, but lower revenue than Cidara Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$925K334.89-$75.14M-$4.35-4.99Cidara Therapeutics$1.27M991.49-$169.83M-$29.47-2.12 SummaryNeurogene beats Cidara Therapeutics on 10 of the 16 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$310.63M$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.16%P/E Ratio-4.9918.0629.1824.41Price / Sales334.89273.22435.00101.08Price / CashN/A40.5624.4827.20Price / Book1.048.628.485.77Net Income-$75.14M-$54.98M$3.24B$264.99M7 Day Performance3.43%-0.87%0.64%-0.68%1 Month Performance8.36%16.08%7.95%7.08%1 Year Performance-40.98%14.18%30.37%23.80% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene2.8297 of 5 stars$21.72-0.3%$46.17+112.6%-45.1%$310.63M$925K-4.9990Positive NewsUpcoming EarningsCDTXCidara Therapeutics2.9032 of 5 stars$62.68+1.3%$57.29-8.6%+425.8%$1.25B$1.27M-2.1390Upcoming EarningsCVACCureVac4.4476 of 5 stars$5.42-0.7%$6.83+26.1%+58.3%$1.22B$579.18M5.89880Positive NewsAUPHAurinia Pharmaceuticals1.679 of 5 stars$8.89-0.4%$11.50+29.4%+108.2%$1.21B$235.13M31.75300Trending NewsEarnings ReportAnalyst RevisionPRAXPraxis Precision Medicines1.9021 of 5 stars$55.65-6.0%$94.11+69.1%-10.0%$1.21B$8.55M-5.19110Trending NewsEarnings ReportGap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PAHCPhibro Animal Health4.2407 of 5 stars$28.92-0.9%$24.40-15.6%+53.0%$1.18B$1.02B37.081,940Positive NewsDividend AnnouncementSRPTSarepta Therapeutics4.6154 of 5 stars$13.86+16.2%$51.42+271.0%-88.1%$1.17B$1.90B-5.151,372Upcoming EarningsDYNDyne Therapeutics3.5864 of 5 stars$9.31-6.4%$40.63+336.4%-74.9%$1.13BN/A-2.59100Upcoming EarningsGap UpSANASana Biotechnology3.3082 of 5 stars$4.88-1.4%$9.17+87.8%-16.1%$1.12BN/A-5.55380News CoverageUpcoming EarningsRCUSArcus Biosciences2.1568 of 5 stars$9.85-3.7%$21.29+116.1%-38.8%$1.08B$258M-2.35500 Related Companies and Tools Related Companies CDTX Alternatives CVAC Alternatives AUPH Alternatives PRAX Alternatives CALT Alternatives PAHC Alternatives SRPT Alternatives DYN Alternatives SANA Alternatives RCUS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NGNE Stock Alerts